Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 − metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study
Breast Cancer · 06.11.2026
DOI: 10.1007/s12282-026-01936-2 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Breast Cancer, online erschienen am 06.11.2026. Verfasst von Takayuki Iwamoto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Pfizer Japan.
Abstract (Originalsprache)
BACKGROUND: Real-world data on PRO-CTCAE-assessed symptomatic toxicities in patients receiving palbociclib (PAL) plus endocrine therapy (ET) remain limited. We evaluated the feasibility of longitudinal assessment and characterized symptom profiles in a multicenter prospective cohort study. METHODS: Patients with HR+/HER2 - metastatic breast cancer receiving PAL plus ET completed paper-based PRO-CTCAE at nine scheduled time points over 6 months. PRO-CTCAE availability was evaluated using the entire analysis population as a fixed denominator. Within-patient changes in general pain, joint pain, and fatigue were assessed, and longitudinal changes in severity were evaluated using cumulative link mixed models (CLMMs). Additional CLMMs examined differences in symptom trajectories between aromatase inhibitor (AI) and fulvestrant (FUL) groups after adjustment for baseline symptom severity, treatment line, and age. RESULTS: Among 593 patients in the original cohort, 414 with baseline paper-based PRO-CTCAE assessments were analyzed. PRO-CTCAE availability was 100% at baseline and 66.4% at 6 months and was comparable across age groups and treatment lines. Significant overall time effects were observed for general pain (P < 0.001), joint pain (P < 0.001), and fatigue (P = 0.007). At 6 months, compared with baseline, the odds of greater symptom severity were lower for general pain (OR 0.49, 95% CI 0.34-0.71) but higher for joint pain (OR 2.36, 95% CI 1.59-3.52) and fatigue (OR 1.82, 95% CI 1.27-2.60). No significant time-by-ET interactions were observed for these symptoms. CONCLUSIONS: Repeated paper-based PRO-CTCAE assessment was feasible and identified distinct longitudinal trajectories of general pain, joint pain, and fatigue during PAL plus ET.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan.
- Biostatistics Section, Department of Data Science, Center for Clinical Sciences, Institute for Health Security, Shinjuku-ku, Japan.
- Department of Breast Surgical Oncology, Tokyo Medical University, Shinjuku-ku, Japan.
- Department of Breast Surgery, Tokyo Medical Center, National Hospital Organization, Meguro-ku, Japan.
- Department of Breast Disease Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
- Department of Breast Surgery, Saitama Red Cross Hospital, Saitama, Japan.
Förderung
- Pfizer Japan
Zitieren
APA
Iwamoto, T., Uemura, Y., Ishikawa, T., Jo, A., Seki, H., Kitada, M., Saito, T., Yamada, K., Takao, S., Takabatake, D., Yokota, T., Hozumi, Y., Kikawa, Y., Yamada, A., Toh, U., Nishimura, H., Kaise, H., Yamagami, K., Nishimura, R., …, & Taira, N. (2026). Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 − metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study. Breast Cancer. https://doi.org/10.1007/s12282-026-01936-2
Vancouver
Iwamoto T, Uemura Y, Ishikawa T, Jo A, Seki H, Kitada M, et al. Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 − metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study. Breast Cancer. 2026. doi:10.1007/s12282-026-01936-2
BibTeX
@article{Iwamoto2026,
author = {Iwamoto, Takayuki and Uemura, Yukari and Ishikawa, Takashi and Jo, Azusa and Seki, Hirohito and Kitada, Masahiro and Saito, Tsuyoshi and Yamada, Kimito and Takao, Shintaro and Takabatake, Daisuke and Yokota, Toru and Hozumi, Yasuo and Kikawa, Yuichiro and Yamada, Akimitsu and Toh, Uhi and Nishimura, Hideki and Kaise, Hiroshi and Yamagami, Kazuhiko and Nishimura, Reiki and Narui, Kazutaka and Mukai, Hirofumi and Taira, Naruto},
title = {Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 − metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study},
journal = {Breast Cancer},
year = {2026},
doi = {10.1007/s12282-026-01936-2}
}
EUVIMED